Biotechs Walk Tightrope On Drug Price Negotiation Messaging
Biotech companies whose products have been affected by Medicare price negotiations under the Inflation Reduction Act largely reassured investors on recent earnings calls of their success, even as they argue in...To view the full article, register now.
Already a subscriber? Click here to view full article